Disclosures: Yousef Almahanna: Nothing to Disclose, Ahmed Almohsen: Nothing to Disclose, Yi Nong Song: Nothing to Disclose, Amani Bajunayd: Nothing to Disclose, Jeemin Kim: Nothing to Disclose, Adrienne Abaya: Nothing to Disclose, Rokhsana Mortuza: Nothing to Disclose, Mohammad Qasim Khan: Nothing to Disclose, Juan Pablo Arab: Nothing to Disclose 1208 DIABETIC MICROVASCULAR COMPLICATIONS ARE ASSOCIATED WITH MORTALITY IN INDIVIDUALS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AND TYPE 2 DIABETES MELLITUS: A NATIONWIDE STUDY Yee Hui Yeo 1 Jie Li 2 Qianqian Chen 2 Wenjing Ni 2 Yixuan Zhu 2 Nan Geng 2 Leyao Jia 2 Fajuan Rui 2 Chao Wu 2 Junping Shi 3 Xiaolong Qi 4 Susan Cheng 5 Amanda Velazquez 6 Alan Kwan 5 Hirsh Trivedi 1 , 1 Cedars-Sinai Medical Center, 2 Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, 3 The Affiliated Hospital of Hangzhou Normal University, 4 Zhongda Hospital, Medical School, Southeast University, Nurturing Center of Jiangsu Province for Sta, 5 Smidt Heart Institute, Cedars-Sinai Medical Center, 6 Center for Weight Management and Metabolic Health, Cedars-Sinai Medical Center Background: Type 2 diabetes mellitus (T2DM) is a key cardiometabolic risk factor of metabolic dysfunction-associated steatotic liver disease (MASLD)
_1772706284.jpg)
W.PopovaA
Together, these nutrients may contribute to a healthier cardiovascular profile
Use of procalcitonin to reduce patients exposure to antibiotics in intensive care units (PRORATA trial): a multicenter randomized controlled trial
In this disease, CD4 T cells differentiate mainly into Th2 cells, whereas Th1 proliferation is inhibited (141)
Histone acetyltransferases
